Cost a focus as GSK takes lead in new wave of biotech lung drugs

September 8, 2014 2:10 PM

4 0

Cost a focus as GSK takes lead in new wave of biotech lung drugs

Ganesh Chaturthi Festival

LONDON (Reuters) - Cost-effectiveness is seen as a challenge for a new group of biotech lung drugs that have produced promising results in clinical tests, of which the first is likely to be launched next year by GlaxoSmithKline.

Read more

To category page

Loading...